Coagulation Signalling and Metabolic Disorders: Lessons Learned from Animal Models

2019 ◽  
Vol 39 (02) ◽  
pp. 164-172 ◽  
Author(s):  
Thati Madhusudhan ◽  
Wolfram Ruf

AbstractNutrient excess in obesity drives metabolic reprogramming in multiple tissues involving extensive interorgan and intercellular crosstalk. Experimental and clinical studies show that prolonged nutrient excess often compromises metabolic adaptation propagating proobesogenic and proinflammatory responses. Chronic inflammation further promotes insulin resistance and associated comorbidities. Obesity and type 2 diabetes are characterized by a hypercoagulable state and clinical studies show a strong correlation of markers of coagulation activation in metabolic disorders. Coagulation protease-dependent signalling via protease-activated receptors is intimately associated with inflammation. The experimental evidence supports roles of tissue factor and G protein coupled protease-activated receptor-2 signalling in the regulation of insulin resistance and metabolic inflammation in diet-induced obesity. Likewise, increases in plasminogen activator inhibitor-1 levels and fibrin-driven inflammation promote insulin resistance in obesity. Additionally, impaired thrombomodulin-dependent protein C activation is mechanistically linked to diabetic kidney disease. Given the increased usage of direct oral anticoagulants, understanding the role of specific coagulation proteases in regulation of metabolic inflammation is highly relevant and might provide insights into the design of novel treatment regimens for patients suffering from thromboinflammatory and cardiometabolic disorders.

Kardiologiia ◽  
2020 ◽  
Vol 60 (10) ◽  
pp. 99-106
Author(s):  
V. A. Ionin

This review focuses on the relevance of sinus rhythm control in patients with atrial fibrillation in real-life clinical practice and specific clinical features of patients with this arrhythmia. The authors presented current guidelines on prevention of thromboembolic complications and a review of results from major clinical studies of direct oral anticoagulants. The search for literature and selection of clinical studies for 2009-2020 were performed on websites of the European and Russian Societies of Cardiology, the All-Russian Scientific Society of Arrhythmologists, and in online databases PubMed, EMBASE, eLibrary, and Google Scholar using the key words atrial fibrillation, anticoagulants, ablation, cardioversion, and efficacy and safety.


Blood ◽  
2015 ◽  
Vol 126 (24) ◽  
pp. 2541-2547 ◽  
Author(s):  
Neil A. Goldenberg ◽  
Clifford M. Takemoto ◽  
Donald L. Yee ◽  
John M. Kittelson ◽  
M. Patricia Massicotte

Abstract Venous thromboembolism (VTE) is increasingly diagnosed in pediatric patients, and anticoagulant use in this population has become common, despite the absence of US Food and Drug Administration (FDA) approval for this indication. Guidelines for the use of anticoagulants in pediatrics are largely extrapolated from large randomized controlled trials (RCTs) in adults, smaller dose-finding and observational studies in children, and expert opinion. The recently FDA-approved direct oral anticoagulants (DOACs), such as dabigatran, rivaroxaban, apixaban, and edoxaban, provide potential advantages over oral vitamin K antagonists and subcutaneous low-molecular-weight heparins (LMWHs). However, key questions arise regarding their potential off-label clinical application in pediatric thromboembolic disease. In this Perspective, we provide background on the use of LMWHs such as enoxaparin as the mainstay of treatment of pediatric provoked VTE; identify key questions and challenges with regard to DOAC trials and future DOAC therapy in pediatric VTE; and discuss applicable lessons learned from the recent pilot/feasibility phase of a large multicenter RCT of anticoagulant duration in pediatric VTE. The challenges and lessons learned present opportunities to improve evidence for anticoagulant therapies in pediatric VTE through future clinical trials.


2015 ◽  
Vol 61 (1) ◽  
pp. 70-82 ◽  
Author(s):  
L.S. Litvinova ◽  
E.V. Kirienkova ◽  
I.O. Mazunin ◽  
M.A. Vasilenko ◽  
N.S. Fattakhov

In this review we discuss the molecular mechanisms of insulin resistance concomitant with metabolic inflammation. We also analyze the world results of experimental and clinical studies which aimed at identifying the molecular targets for the development of new prevention and treatment of insulin resistance.


Author(s):  
Nazarii Kobyliak ◽  
Tetyana Falalyeyeva ◽  
Galyna Mykhalchyshyn ◽  
Olexiy Savchuk ◽  
Dmytro Kyriienko ◽  
...  

2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Gabriello Marchetti ◽  
Francesco Bernardini ◽  
Michele Romoli ◽  
Stefano Urbinati

Sign in / Sign up

Export Citation Format

Share Document